Yesterday it was reported that a Director at Transenterix (TRXC – Research Report), David Bruce Milne, exercised options to sell 147,058 TRXC shares at $0.68 a share, for a total transaction value of $308.8K. The options were close to expired and David Bruce Milne disposed stocks.
Currently, Transenterix has an average volume of 49.76M. TRXC’s market cap is $241 million and the company has a P/E ratio of -1.50. The company has a one-year high of $2.29 and a one-year low of $0.28.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. It offers the Senhance Surgical Robotic System, which offers robotic surgery for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, and the SurgiBot System which refers to the a single-port, robotically enhanced laparoscopic surgical platform. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.